<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK25442" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK25442/" /><meta name="ncbi_pagename" content="Episodic Ataxia Type 1 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Episodic Ataxia Type 1 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Episodic Ataxia Type 1" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/11/01" /><meta name="citation_author" content="Sonia M Hasan" /><meta name="citation_author" content="Maria Cristina D'Adamo" /><meta name="citation_pmid" content="20301785" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK25442/" /><meta name="citation_keywords" content="EA1" /><meta name="citation_keywords" content="EA1" /><meta name="citation_keywords" content="Potassium voltage-gated channel subfamily A member 1" /><meta name="citation_keywords" content="KCNA1" /><meta name="citation_keywords" content="Episodic Ataxia Type 1" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Episodic Ataxia Type 1" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Sonia M Hasan" /><meta name="DC.Contributor" content="Maria Cristina D'Adamo" /><meta name="DC.Date" content="2018/11/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK25442/" /><meta name="description" content="Episodic ataxia type 1 (EA1) is a potassium channelopathy characterized by constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks individuals may experience a number of variable symptoms including vertigo, blurred vision, diplopia, nausea, headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing, among others. EA1 may be associated with epilepsy. Other possible associations include delayed motor development, cognitive disability, choreoathetosis, and carpal spasm. Usually, onset is in childhood or early adolescence." /><meta name="og:title" content="Episodic Ataxia Type 1" /><meta name="og:type" content="book" /><meta name="og:description" content="Episodic ataxia type 1 (EA1) is a potassium channelopathy characterized by constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks individuals may experience a number of variable symptoms including vertigo, blurred vision, diplopia, nausea, headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing, among others. EA1 may be associated with epilepsy. Other possible associations include delayed motor development, cognitive disability, choreoathetosis, and carpal spasm. Usually, onset is in childhood or early adolescence." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK25442/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ea1/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK25442/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE896F1AE040D5C10000000004EF0236.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK25442_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK25442_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/gale-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ea2/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK25442_"><span class="title" itemprop="name">Episodic Ataxia Type 1</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: EA1</div><p class="contrib-group"><span itemprop="author">Sonia M Hasan</span>, PhD and <span itemprop="author">Maria Cristina D'Adamo</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK25442_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK25442_ai__"><div class="contrib half_rhythm"><span itemprop="author">Sonia M Hasan</span>, PhD<div class="affiliation small">Department of Physiology<br />Faculty of Medicine<br />Kuwait University<br />Kuwait City, Kuwait<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="wk.ude.csh@ainos" class="oemail">wk.ude.csh@ainos</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Maria Cristina D'Adamo</span>, PhD<div class="affiliation small">Department of Physiology and Biochemistry<br />University of Malta<br />Msida, Malta<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="tm.ude.mu@omadad.anitsirc" class="oemail">tm.ude.mu@omadad.anitsirc</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 9, 2010</span>; Last Revision: <span itemprop="dateModified">November 1, 2018</span>.</p><p><em>Estimated reading time: 30 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ea1.Summary" itemprop="description"><h2 id="_ea1_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Episodic ataxia type 1 (EA1) is a potassium channelopathy characterized by constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks individuals may experience a number of variable symptoms including vertigo, blurred vision, diplopia, nausea, headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing, among others. EA1 may be associated with epilepsy. Other possible associations include delayed motor development, cognitive disability, choreoathetosis, and carpal spasm. Usually, onset is in childhood or early adolescence.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Diagnosis is based on clinical findings, an electrophysiologic test of axonal superexcitability and threshold electrotonus, and/or the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KCNA1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Acetazolamide, a carbonic-anhydrase inhibitor, may reduce the frequency and severity of attacks in some but not all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Antiepileptic drugs may significantly reduce the frequency of attacks in some individuals. Supportive therapies, such as physical therapy, may reduce the risk of later-onset orthopedic complications. Routine treatment of seizure disorders, scoliosis, and developmental disabilities.</p><p><i>Prevention of primary manifestations</i>: In addition to pharmacologic treatments, behavioral measures including avoidance of stress, abrupt movements, loud noises, and caffeine may be used to reduce disease manifestations in both symptomatic and asymptomatic individuals.</p><p><i>Prevention of secondary complications:</i> Joint contractures can be prevented by appropriate physiotherapy.</p><p><i>Surveillance:</i> Annual neurologic examination.</p><p><i>Agents/circumstances to avoid:</i> Triggers of attacks, including physical exertion, emotional stress, and changes in environmental temperature; marked generalized myokymia has been reported during induction of anesthesia.</p><p><i>Pregnancy management:</i> Affected women should be made aware that pregnancy may trigger attacks; possible loss of balance and falls could endanger the fetus. Several stressors that trigger attacks may cause breathing difficulties; thus, delivery by C-section should be considered.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>EA1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Most individuals diagnosed with EA1 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent; however, <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants have been reported. Each child of an individual with EA1 has a 50% chance of inheriting the <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant has been identified in an affected family member.</p></div></div><div id="ea1.Diagnosis"><h2 id="_ea1_Diagnosis_">Diagnosis</h2><p>No consensus diagnostic criteria for episodic ataxia type 1 (EA1) have been published.</p><div id="ea1.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Episodic ataxia type 1 (EA1) <b>should be suspected</b> in individuals with the following clinical, imaging, and laboratory findings.</p><p><b>Clinical manifestations</b></p><ul><li class="half_rhythm"><div>Episodic attacks of:</div><ul><li class="half_rhythm"><div>Generalized ataxia, loss of balance, and jerking movements of the head, arms, and legs</div></li><li class="half_rhythm"><div>Dysarthria</div></li><li class="half_rhythm"><div>Incoordination of hands</div></li><li class="half_rhythm"><div>Weakness</div></li><li class="half_rhythm"><div>Tremors</div></li><li class="half_rhythm"><div>Muscle twitching/stiffening</div></li><li class="half_rhythm"><div>Dizziness</div></li><li class="half_rhythm"><div>Stiffening of the body</div></li><li class="half_rhythm"><div>Blurred vision, diplopia</div></li><li class="half_rhythm"><div>Nausea, headache, and vomiting</div></li></ul></li><li class="half_rhythm"><div>Neuromyotonia (muscle cramps and stiffness)</div></li><li class="half_rhythm"><div>Myokymia (muscle twitching with a rippling appearance) occurring in the limbs or especially in the muscles of the face or hands</div></li><li class="half_rhythm"><div>Childhood or early-adolescent disease onset (average age of onset: ~8 years)</div></li></ul><p><b>Imaging and laboratory findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Normal brain MRI</div></li><li class="half_rhythm"><div class="half_rhythm">Routine laboratory blood tests including serum concentration of creatine kinase and electrolytes</div></li><li class="half_rhythm"><div class="half_rhythm">EMG that displays a pattern of either rhythmically or arrhythmically occurring singlets, duplets, or multiplets</div><div class="half_rhythm">Note: In some individuals myokymic activity on the EMG becomes apparent after the application of regional ischemia.</div><ul><li class="half_rhythm"><div>To evaluate for interictal motor activity (neuromyotonia/myokymia): surface or needle EMG recordings are performed before, during, and after the application of regional ischemia (e.g., using an inflated sphygmomanometer cuff applied around the upper or lower arm for up to 15 minutes).</div></li><li class="half_rhythm"><div>In specialized centers, electrophysiologic assessments of axonal superexcitability and threshold electrotonus performed according to the TRONDHM protocol (using Qtrac<sup>&#x000a9;</sup> software; UCL Institute of Neurology [<a class="bk_pop" href="#ea1.REF.kiernan.2000.399">Kiernan et al 2000</a>]) differentiate individuals with EA1 from normal controls with high <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity [<a class="bk_pop" href="#ea1.REF.tomlinson.2010.3530">Tomlinson et al 2010</a>].</div></li></ul></li></ul><p><b>Family history.</b> Consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</p><p>Note: (1) Lack of a family history of EA1 does not preclude the diagnosis. (2) Muscle biopsy is usually not helpful in establishing the diagnosis, although bilateral calf hypertrophy, enlargement of type 1 and type 2 gastrocnemius muscle fibers, abnormal mitochondria, and variable glycogen depletion have been observed [<a class="bk_pop" href="#ea1.REF.vandyke.1975.109">VanDyke et al 1975</a>, <a class="bk_pop" href="#ea1.REF.kinali.2004.689">Kinali et al 2004</a>, <a class="bk_pop" href="#ea1.REF.demos.2009.778">Demos et al 2009</a>, <a class="bk_pop" href="#ea1.REF.brownstein.2016.11">Brownstein et al 2016</a>]. Nevertheless, these changes have not been consistently reported among individuals with EA1.</p></div><div id="ea1.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of EA1 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by means of electrophysiology assessments and/or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KCNA1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK25442/table/ea1.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figea1Tmoleculargenetictestingusedin" rid-ob="figobea1Tmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of EA1 is broad, individuals with the distinctive findings described in <a href="#ea1.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#ea1.Option_1">Option 1</a>), whereas those in whom the diagnosis of EA1 has not been considered are more likely to be diagnosed using genomic testing (see <a href="#ea1.Option_2">Option 2</a>).</p><div id="ea1.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of EA1 <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>KCNA1</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. Although deletions of <i>KCNA1</i> have not as yet been reported to cause EA1, it is theoretically possible that such deletions may occur. Therefore, gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>KCNA1</i> may be considered if sequence analysis does not identify a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>KCNA1</i> and other genes of interest (see <a href="#ea1.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="ea1.Option_2"><h4>Option 2</h4><p>When the diagnosis of EA1 is not considered because an individual has atypical or complex phenotypic features, <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option [<a class="bk_pop" href="#ea1.REF.tacik.2015.366">Tacik et al 2015</a>]. <b>Exome sequencing</b> is the most commonly used genomic testing method; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="ea1.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Episodic Ataxia Type 1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25442/table/ea1.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ea1.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>KCNA1</i></td><td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ea1.TF.1.1"><p class="no_margin">See <a href="/books/NBK25442/#ea1.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ea1.TF.1.2"><p class="no_margin">See <a href="#ea1.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ea1.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ea1.TF.1.4"><p class="no_margin">All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals described thus far are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for <i>KCNA1</i> pathogenic variants at amino acid residues highly conserved among the voltage-dependent K<sup>+</sup> channel superfamily.</p></div></dd><dt>5. </dt><dd><div id="ea1.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="ea1.TF.1.6"><p class="no_margin">No deletions or duplications of <i>KCNA1</i> have been reported to cause EA1.</p></div></dd></dl></div></div></div><p><b>Interpretation of test results.</b> For <i>KCNA1</i> sequence variants, publications on in vitro assessment of channel function may be useful [<a class="bk_pop" href="#ea1.REF.dadamo.1998.1200">D'Adamo et al 1998</a>, <a class="bk_pop" href="#ea1.REF.dadamo.1999.1335">D'Adamo et al 1999</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2008.577">Imbrici et al 2008</a>, <a class="bk_pop" href="#ea1.REF.dadamo.2015b.317">D'Adamo et al 2015b</a>, <a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al 2017</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2017.6">Imbrici et al 2017</a>]. Channel function assays are not offered on a clinical testing basis.</p></div></div></div><div id="ea1.Clinical_Characteristics"><h2 id="_ea1_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ea1.Clinical_Description"><h3>Clinical Description</h3><p>Episodic ataxia type 1 (EA1), first described by <a class="bk_pop" href="#ea1.REF.vandyke.1975.109">VanDyke et al [1975]</a>, is a potassium channelopathy characterized by constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance.</p><p><b>Typical attacks in individuals with EA1.</b> In addition to the features noted in <a href="#ea1.Suggestive_Findings">Suggestive Findings</a>, <b>Clinical manifestations</b>, individuals may experience the following symptoms:</p><ul><li class="half_rhythm"><div>Vertigo</div></li><li class="half_rhythm"><div>Diaphoresis</div></li><li class="half_rhythm"><div>Clumsiness</div></li><li class="half_rhythm"><div>Difficulty in breathing, which can occur during ataxic episodes or as isolated episodes [<a class="bk_pop" href="#ea1.REF.shook.2008.399">Shook et al 2008</a>]</div></li></ul><p>The duration of the attacks is brief, lasting seconds to minutes, although prolonged attacks lasting hours have been described [<a class="bk_pop" href="#ea1.REF.lee.2004a.536">Lee et al 2004a</a>, <a class="bk_pop" href="#ea1.REF.dadamo.2015a.525">D'Adamo et al 2015a</a>]. Episode occurrence is variable, with some individuals experiencing severe ataxia more than 15 times per day and others experiencing attacks less often than once a month.</p><p>The first symptoms typically manifest in the first or second decade of life.</p><p><b>Less common symptoms during attacks</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Choreoathetosis</div></li><li class="half_rhythm"><div class="half_rhythm">Carpal spasm</div></li><li class="half_rhythm"><div class="half_rhythm">Clenching of the fists</div></li><li class="half_rhythm"><div class="half_rhythm">Mild lower limb sensory impairment</div></li><li class="half_rhythm"><div class="half_rhythm">Isolated neuromyotonia</div></li><li class="half_rhythm"><div class="half_rhythm">Nystagmus [<a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al 2017</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Hyperthermia [<a class="bk_pop" href="#ea1.REF.dadamo.2015a.525">D'Adamo et al 2015a</a>, <a class="bk_pop" href="#ea1.REF.mestre.2016.245">Mestre et al 2016</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">Hypothermia, which led to the death of an individual with EA1 due to exposure to anesthesia [<a class="bk_pop" href="#ea1.REF.mestre.2016.245">Mestre et al 2016</a>]</div><div class="half_rhythm">Note: Anesthetic agents have an inhibitory effect on kv1.1 channels.</div></li></ul><p><b>Triggers.</b> A specific traumatic event, physical or emotional, may determine the onset and worsening of the disease [<a class="bk_pop" href="#ea1.REF.imbrici.2008.577">Imbrici et al 2008</a>]. Attacks may be brought on by the following stimuli:</p><ul><li class="half_rhythm"><div>Stress or anxiety</div></li><li class="half_rhythm"><div>Intercurrent illness or fever</div></li><li class="half_rhythm"><div>Excitement or emotional upset</div></li><li class="half_rhythm"><div>Fatigue</div></li><li class="half_rhythm"><div>Menstruation or pregnancy</div></li><li class="half_rhythm"><div>Environmental temperature, including hot baths or use of a hairdryer [<a class="bk_pop" href="#ea1.REF.eunson.2000.647">Eunson et al 2000</a>]</div></li><li class="half_rhythm"><div>Startle response</div></li><li class="half_rhythm"><div>Abrupt movements or sudden postural changes (kinesigenic stimulation), including riding a merry-go-round</div></li><li class="half_rhythm"><div>Vestibular stimulation (turning head from side to side while standing still; sitting still on a rotating chair; instillation of cold water [i.e., &#x02264;30&#x000b0; C] into either external auditory canal)</div></li><li class="half_rhythm"><div>Exercise, such as repeat knee bends</div></li><li class="half_rhythm"><div>Ingestion of the following:</div><ul><li class="half_rhythm"><div>Caffeine</div></li><li class="half_rhythm"><div>Alcohol</div></li><li class="half_rhythm"><div>Foods rich in salt</div></li><li class="half_rhythm"><div>Bitter oranges</div></li><li class="half_rhythm"><div>Chocolate</div></li></ul></li></ul><p>Interictal ataxia has not been reported to date in individuals with EA1.</p><p><b>Myokymia</b> manifests clinically during and between attacks as fine twitching of groups of muscles and intermittent cramps and stiffness. The severity of some symptoms may either improve or worsen with age [<a class="bk_pop" href="#ea1.REF.imbrici.2008.577">Imbrici et al 2008</a>].</p><ul><li class="half_rhythm"><div>Myokymia is typically evident as a fine rippling in the perioral or periorbital muscles and by lateral finger movements when the hands are held in a relaxed, prone position.</div></li><li class="half_rhythm"><div>Exposure of the forearm to warm or cold temperatures may increase or decrease, respectively, the spontaneous activity recorded from a hand muscle.</div></li><li class="half_rhythm"><div>Rarely, episodes of intense myokymic activity during attacks without either ataxia or other neurologic deficits may be observed.</div></li><li class="half_rhythm"><div>Myokymic activity is continuous and present in almost all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ea1.REF.lee.2004b.3161">Lee et al 2004b</a>, <a class="bk_pop" href="#ea1.REF.dadamo.2015a.525">D'Adamo et al 2015a</a>].</div></li></ul><p><b>Cognitive dysfunction</b> includes the following:</p><ul><li class="half_rhythm"><div>Severe receptive and expressive language delay</div></li><li class="half_rhythm"><div>Inability to learn to ride a bicycle</div></li><li class="half_rhythm"><div>The need for life-skill programs or schools for children with mild to moderate learning difficulties [<a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al 1999</a>, <a class="bk_pop" href="#ea1.REF.demos.2009.778">Demos et al 2009</a>]</div></li></ul><p><b>Neuromuscular findings</b></p><ul><li class="half_rhythm"><div>Moderate muscle hypertrophy with generalized increase in muscle tone and bilateral calf hypertrophy are observed.</div></li><li class="half_rhythm"><div>Increased muscle tone can cause the following:</div><ul><li class="half_rhythm"><div>Unusual hypercontracted posture</div></li><li class="half_rhythm"><div>Abdominal wall muscle contraction</div></li><li class="half_rhythm"><div>Elbow, hip, and knee contractures</div></li><li class="half_rhythm"><div>Shortened Achilles tendons that may result in tiptoe walking</div></li></ul></li></ul><p><b>Seizures.</b> Tonic-clonic and partial seizures, an isolated episode consisting of photo-sensitive epilepsy [<a class="bk_pop" href="#ea1.REF.imbrici.2008.577">Imbrici et al 2008</a>], as well as head-turning and eyes deviating to the same side, flickering eyelids, lip-smacking, apnea, and cyanosis have been reported [<a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al 1999</a>]. Prolonged episodes (more than 30 minutes) have been reported in an individual with severe early-onset epilepsy, albeit without the typical ataxia [<a class="bk_pop" href="#ea1.REF.rogers.2018.1748">Rogers et al 2018</a>].</p><p><b>Other anomalies</b> [<a class="bk_pop" href="#ea1.REF.kinali.2004.689">Kinali et al 2004</a>, <a class="bk_pop" href="#ea1.REF.klein.2004.147">Klein et al 2004</a>]</p><ul><li class="half_rhythm"><div>Scoliosis</div></li><li class="half_rhythm"><div>Kyphoscoliosis</div></li><li class="half_rhythm"><div>High-arched palate</div></li><li class="half_rhythm"><div>Minor craniofacial dysmorphism</div></li></ul><p><b>Electroencephalogram (EEG)</b> abnormalities have been observed in persons with EA1 [<a class="bk_pop" href="#ea1.REF.vandyke.1975.109">VanDyke et al 1975</a>, <a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al 1999</a>, <a class="bk_pop" href="#ea1.REF.lee.2004a.536">Lee et al 2004a</a>].</p><ul><li class="half_rhythm"><div>EEG may be characterized by intermittent and generalized slow activity, frequently intermingled with spikes.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al [1999]</a> described a boy age three years who presented with an ictal EEG with rhythmic slow-wave activity over the right hemisphere, becoming spike-and-wave complexes that subsequently spread to the left hemisphere.</div></li></ul><p><b>Compound muscle action potentials (CMAP) from electromyography (EMG)</b> showed presence of repetitive components of CMAP in ulnar as well as in tibial nerves. They were evident both on routine motor studies and on F-wave studies, making F-waves unrecognizable [<a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al 2017</a>].</p><ul><li class="half_rhythm"><div>Sensory conduction test results were normal.</div></li><li class="half_rhythm"><div>Abnormal neuromuscular transmission was reported from <a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al [2017]</a> after a train of stimuli at 20 Hz or 50 Hz that resulted in a decrement of the amplitude of the first CMAP elicited followed by an increment of the second CMAP amplitude elicited (decrement-increment phenomenon), similar to what is usually observed in organophosphate intoxication.</div></li></ul><p><b>Brain MRI</b> is usually normal; however, rare findings include the following:</p><ul><li class="half_rhythm"><div>Cerebellar atrophy in one family [<a class="bk_pop" href="#ea1.REF.demos.2009.778">Demos et al 2009</a>]</div></li><li class="half_rhythm"><div>Mild vermian hypoplasia [<a class="bk_pop" href="#ea1.REF.tacik.2015.366">Tacik et al 2015</a>]</div></li><li class="half_rhythm"><div>Small right subcortical frontal gliosis [<a class="bk_pop" href="#ea1.REF.brownstein.2016.11">Brownstein et al 2016</a>]</div></li></ul></div><div id="ea1.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Due to significant inter- and intrafamilial phenotypic variability, reliable <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been extremely difficult to establish. It is now apparent that phenotypic differences exist not only across families, but also among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals within a family. Indeed, differences in severity and frequency of EA1 attacks have been reported even in monozygotic twins [<a class="bk_pop" href="#ea1.REF.graves.2010.367">Graves et al 2010</a>].</p></div><div id="ea1.Penetrance"><h3>Penetrance</h3><p>Most individuals harboring a <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> exhibit features of EA1; however, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is incomplete.</p></div><div id="ea1.Nomenclature"><h3>Nomenclature</h3><p>EA1 has also been known as:</p><ul><li class="half_rhythm"><div>Acetazolamide-responsive periodic ataxia</div></li><li class="half_rhythm"><div>Continuous muscle fiber activity</div></li><li class="half_rhythm"><div>Episodic ataxia with myokymia</div></li><li class="half_rhythm"><div>Familial paroxysmal kinesigenic ataxia and continuous myokymia</div></li><li class="half_rhythm"><div>Isaacs-Mertens syndrome</div></li><li class="half_rhythm"><div>Hereditary paroxysmal ataxia with neuromyotonia</div></li></ul></div><div id="ea1.Prevalence"><h3>Prevalence</h3><p>EA1 is a rare disease and the prevalence can be estimated only roughly. Several families from Australia, Brazil, Canada, Germany, Italy, Russia, Spain, the Netherlands, United Kingdom, and the United States have been described. Based on limited data, a disease prevalence of 1:500,000 has been proposed. Actual prevalence may well be considerably higher, as the disorder may remain either unrecognized in many families or be incorrectly diagnosed.</p><p>The populations that are more or less at risk are also unknown.</p></div></div><div id="ea1.Genetically_Related_Allelic_Disorder"><h2 id="_ea1_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>It is unclear whether the following truly represent unique phenotypes associated with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>KCNA1</i> or fall within the phenotypic spectrum of episodic ataxia type 1 (EA1). While episodic onset of neurologic features remains a key feature in individuals with a pathogenic variant in <i>KCNA1</i>, ataxia may not be present. Whether episodic "ataxia" is a misnomer, as suggested by <a class="bk_pop" href="#ea1.REF.brownstein.2016.11">Brownstein et al [2016]</a>, will be revealed as more individuals undergo <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> evaluation.</p><ul><li class="half_rhythm"><div><a class="bk_pop" href="#ea1.REF.eunson.2000.647">Eunson et al [2000]</a> reported <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> neuromyotonia without episodes of ataxia.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#ea1.REF.brownstein.2016.11">Brownstein et al [2016]</a> reported cataplexy triggered by sudden physical exertion in multiple individuals of a three-generation family, and muscle spasms with rigidity in another family.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#ea1.REF.dadamo.2015a.525">D'Adamo et al [2015a]</a> reported a unique <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> characterized by episodes of long-lasting attacks with hyperthermia, short sleep duration, and severe migraine.</div></li><li class="half_rhythm"><div>Hypomagnesemia with accompanying recurrent muscle cramps, tetanic episodes, tremor, and limb muscle weakness has been described in a large Brazilian family harboring a <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#ea1.REF.glaudemans.2009.936">Glaudemans et al 2009</a>].</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#ea1.REF.trist_nclavijo.2016.1743">Trist&#x000e1;n-Clavijo et al [2016]</a> reported a Spanish family with migraine and tremor without ataxia.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#ea1.REF.set.2017.784">Set et al [2017]</a> reported an individual with episodes of bilateral stiffening of the lower extremities lasting for two to 12 hours, with no ataxia or myokymia.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#ea1.REF.rogers.2018.1748">Rogers et al [2018]</a> reported early onset epileptic encephalopathy and cognitive impairment without ataxia.</div></li></ul></div><div id="ea1.Differential_Diagnosis"><h2 id="_ea1_Differential_Diagnosis_">Differential Diagnosis</h2><p>Episodic ataxia can occur sporadically or in a number of hereditary or acquired disorders.</p><div id="ea1.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Episodic Ataxia Type 1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25442/table/ea1.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ea1.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Features</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Onset</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency of Attacks</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Attack Triggers</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Interictal Findings</th></tr></thead><tbody><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ea2/">EA2</a>&#x000a0;<sup>1</sup></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CACNA1A</i></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Paroxysmal attacks of ataxia, vertigo, nausea lasting minutes to days; can be assoc'd w/dysarthria, diplopia, tinnitus, dystonia, hemiplegia, &#x00026; headache (migraine in ~50%)</div></li><li class="half_rhythm"><div>Atrophy of cerebellar vermis on MRI</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically childhood or early adolescence (range: 2-32 yrs)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range: 1-2/yr to 3-4/wk</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Stress</div></li><li class="half_rhythm"><div>Exertion</div></li><li class="half_rhythm"><div>Caffeine</div></li><li class="half_rhythm"><div>Alcohol</div></li><li class="half_rhythm"><div>Fever</div></li><li class="half_rhythm"><div>Heat</div></li><li class="half_rhythm"><div>Phenytoin</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acetazolamide can stop or &#x02193; attack frequency/severity.</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Initially asymptomatic; may develop interictal findings incl nystagmus &#x00026; ataxia</td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EA3&#x000a0;<sup>2</sup><br />(OMIM <a href="https://omim.org/entry/606554" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606554</a>)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Vestibular ataxia</div></li><li class="half_rhythm"><div>Vertigo</div></li><li class="half_rhythm"><div>Tinnitus</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myokymia</td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EA4&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5</sup><br />(OMIM <a href="https://omim.org/entry/606552" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606552</a>)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Recurrent attacks of vertigo, tinnitus, diplopia, &#x00026; ataxia</div></li><li class="half_rhythm"><div>Abnormal eye movements (incl abnormal smooth pursuit, nystagmus, &#x00026; abnormal vestibuloocular reflex)</div></li><li class="half_rhythm"><div>Slowly progressive cerebellar ataxia in some</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early adulthood (range: 3rd-6th decade)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No response to acetazolamide</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absence of interictal myokymia</td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EA5<br />(OMIM <a href="https://omim.org/entry/613855" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613855</a>)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CACNB4</i>&#x000a0;<sup>6</sup></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Recurrent episodes of vertigo &#x00026; ataxia lasting several hours&#x000a0;<sup>6</sup></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acetazolamide prevented attacks.</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spontaneous downbeat &#x00026; gaze-evoked nystagmus, mild dysarthria, &#x00026; truncal ataxia</td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EA6<br />(OMIM <a href="https://omim.org/entry/612656" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612656</a>)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC1A3</i>&#x000a0;<sup>7</sup></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Attacks of ataxia precipitated by fever</div></li><li class="half_rhythm"><div>Subclinical seizures</div></li><li class="half_rhythm"><div>Slurred speech followed by headache</div></li><li class="half_rhythm"><div>Bouts of arm jerking w/concomitant confusion</div></li><li class="half_rhythm"><div>Alternating hemiplegia</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Stress</div></li><li class="half_rhythm"><div>Fatigue</div></li><li class="half_rhythm"><div>Caffeine</div></li><li class="half_rhythm"><div>Alcohol</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gaze-evoked nystagmus</td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EA7<br />(OMIM <a href="https://omim.org/entry/611907" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611907</a>)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>8</sup></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Attacks assoc'd w/weakness, vertigo, &#x00026; dysarthria lasting hrs to days</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Before age 20 years</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range: 1/mo to 1/yr; frequency tends to &#x02193; w/age.</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Exercise</div></li><li class="half_rhythm"><div>Excitement</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EA8&#x000a0;<sup>9</sup><br />(OMIM <a href="https://www.omim.org/entry/611907" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616055</a>)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Unsteady gait, generalized weakness, &#x00026; slurred speech lasting mins to hrs</div></li><li class="half_rhythm"><div>In 2 women: improvement during pregnancy; in others: &#x02193; frequency &#x00026; severity of attacks w/age</div></li><li class="half_rhythm"><div>Twitching around eyes, nystagmus, myokymia, mild dysarthria, &#x00026; persistent intention tremor in some</div></li><li class="half_rhythm"><div>Migraine headache w/out aura reported in 2 individuals</div></li><li class="half_rhythm"><div>Epilepsy not reported</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2nd year of life</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range: 2/day to 2/mo</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clonazepam was effective.</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spastic ataxia 1<br />(OMIM <a href="https://www.omim.org/entry/108600" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">108600</a>)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VAMP1</i></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Initially, progressive leg spasticity of variable degree followed by ataxia (involuntary head jerk, dysarthria, dysphagia, &#x00026; ocular movement abnormalities)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early childhood - early 20s</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/prrt2-parox/">Familial paroxysmal kinesigenic dyskinesia</a>&#x000a0;<sup>10</sup></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PRRT2</i></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Unilateral or bilateral involuntary movements</div></li><li class="half_rhythm"><div>Attacks usually last a few secs to 5 mins but can last several hrs &#x00026; incl dystonia, choreoathetosis, &#x00026;/or ballism</div></li><li class="half_rhythm"><div>May be preceded by aura, &#x00026; do not involve loss of consciousness</div></li><li class="half_rhythm"><div>Severity &#x00026; combinations of symptoms vary</div></li><li class="half_rhythm"><div>Predominantly seen in males</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically childhood &#x00026; adolescence (range 4 mos - 57 yrs)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Range: 100/day to as few as 1/mo</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sudden movements (e.g., standing up from sitting position, being startled, or changes in velocity)</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenytoin or carbamezepine can &#x02193; frequency of (or prevent) attacks.</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pnknd/">Familial paroxysmal nonkinesigenic dyskinesia</a></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PNKD</i></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Unilateral or bilateral involuntary movements</div></li><li class="half_rhythm"><div>Attacks lasting mins to hrs: dystonic posturing w/choreic &#x00026; ballistic movements; may be preceded by aura; occur while awake; are not associated w/seizures</div></li><li class="half_rhythm"><div>Frequency, duration, severity, &#x00026; combinations of symptoms vary w/in &#x00026; among families</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically in childhood or early teens; can be as late as age 50 yrs</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">A few times/day</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Attacks are spontaneous or precipitated by:
<ul><li class="half_rhythm"><div>Alcohol</div></li><li class="half_rhythm"><div>Caffeine</div></li><li class="half_rhythm"><div>Excitement</div></li><li class="half_rhythm"><div>Stress</div></li><li class="half_rhythm"><div>Fatigue</div></li><li class="half_rhythm"><div>Chocolate</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Isaac syndrome (acquired neuromyotonia, NMT)&#x000a0;<sup>11</sup></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Rare neuromuscular disorder</div></li><li class="half_rhythm"><div>Hyperexcitability of motor nerve &#x02192; continuously contracting or twitching muscles (myokymia) &#x00026; muscle hypertrophy</div></li><li class="half_rhythm"><div>Cramping, &#x02191; sweating, &#x00026; delayed muscle relaxation</div></li><li class="half_rhythm"><div>Stiffness most prominent in limb &#x00026; trunk muscles</div></li><li class="half_rhythm"><div>A few patients report sleep disorders, anxiety, &#x00026; memory loss (Morvan syndrome)</div></li></ul>
</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15-60 years</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Symptoms not usually triggered by exercise; occur even during sleep or under general anesthesia</td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_ea1.T.disorders_to_consider_in_the_diffe_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>: MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; N/A = not applicable</p></div></dd><dt></dt><dd><div><p class="no_margin">See <a href="http://omim.org/phenotypicSeries/PS160120" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Episodic ataxia: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div></dd><dt>1. </dt><dd><div id="ea1.TF.2.1"><p class="no_margin">EA2 is allelic to <a href="/books/n/gene/sca6/">SCA6</a> and <a href="/books/n/gene/fhm/">familial hemiplegic migraine type 1</a>.</p></div></dd><dt>2. </dt><dd><div id="ea1.TF.2.2"><p class="no_margin">EA3 has been described in a large Canadian kindred of Mennonite heritage [<a class="bk_pop" href="#ea1.REF.steckley.2001.1499">Steckley et al 2001</a>].</p></div></dd><dt>3. </dt><dd><div id="ea1.TF.2.3"><p class="no_margin">EA4 (also referred to as periodic vestibulocerebellar ataxia) has been described in families from North Carolina of northern European origin by <a class="bk_pop" href="#ea1.REF.farmer.1963.471">Farmer &#x00026; Mustian [1963]</a> and <a class="bk_pop" href="#ea1.REF.vance.1984.78s">Vance et al [1984]</a>.</p></div></dd><dt>4. </dt><dd><div id="ea1.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#ea1.REF.steckley.2001.1499">Steckley et al [2001]</a></p></div></dd><dt>5. </dt><dd><div id="ea1.TF.2.5"><p class="no_margin">EA4 does not link to loci identified with EA1, EA2, or spinocerebellar ataxia types 1, 2, 3, 4, and 5 [<a class="bk_pop" href="#ea1.REF.damji.1996.338">Damji et al 1996</a>].</p></div></dd><dt>6. </dt><dd><div id="ea1.TF.2.6"><p class="no_margin">EA5 can result from pathogenic variants in <i>CACNB4</i> as described in a French-Canadian family [<a class="bk_pop" href="#ea1.REF.escayg.2000.1531">Escayg et al 2000</a>]. EA5 is allelic with susceptibility to juvenile myoclonic epilepsy 6 (EJM6, OMIM <a href="https://www.omim.org/entry/607682" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607682</a>); the semiology of seizures in EA5 is similar to EJM6.</p></div></dd><dt>7. </dt><dd><div id="ea1.TF.2.7"><p class="no_margin">EA6 can result from pathogenic variants in <i>SLC1A3</i>, which encodes the excitatory amino acid transporter 1. In cells expressing mutated proteins, glutamate uptake is reduced, suggesting that glutamate transporter dysfunction underlies the disease [<a class="bk_pop" href="#ea1.REF.jen.2005.529">Jen et al 2005</a>, <a class="bk_pop" href="#ea1.REF.de_vries.2009.97">de Vries et al 2009</a>].</p></div></dd><dt>8. </dt><dd><div id="ea1.TF.2.8"><p class="no_margin">EA7 has been described in a four-generation family whose <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals showed episodic ataxia [<a class="bk_pop" href="#ea1.REF.kerber.2007.749">Kerber et al 2007</a>]. A candidate region on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 19q13, termed the EA7 <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>, has been identified [<a class="bk_pop" href="#ea1.REF.kerber.2007.749">Kerber et al 2007</a>].</p></div></dd><dt>9. </dt><dd><div id="ea1.TF.2.9"><p class="no_margin">Genome-wide linkage analysis found linkage to an 18.5-Mb <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 1p36.13-p34.3 [<a class="bk_pop" href="#ea1.REF.conroy.2014.505">Conroy et al 2014</a>].</p></div></dd><dt>10. </dt><dd><div id="ea1.TF.2.10"><p class="no_margin">The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of paroxysmal kinesigenic dyskinesia can include benign <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> infantile epilepsy (BFIE), infantile convulsions and choreoathetosis (ICCA), hemiplegic migraine, migraine with and without aura, and episodic ataxia.</p></div></dd><dt>11. </dt><dd><div id="ea1.TF.2.11"><p class="no_margin">The acquired form of Isaac's syndrome occasionally develops in association with peripheral neuropathies or after radiation treatment. Twenty percent of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have an associated thymoma. Antibodies that involve K+ channels have been detected in approximately 40% of affected individuals [<a class="bk_pop" href="#ea1.REF.hart.2002.1887">Hart et al 2002</a>]. Several of these auto-antibodies do not bind directly with Kv1.1, Kv1.2, or Kv1.6 channels, as previously believed, but rather to associated proteins such as leucine-rich glioma-inactivated protein 1, contactin-associated protein-like 2, contactin-2, or others as yet unidentified [<a class="bk_pop" href="#ea1.REF.irani.2010.2734">Irani et al 2010</a>, <a class="bk_pop" href="#ea1.REF.lai.2010.776">Lai et al 2010</a>, <a class="bk_pop" href="#ea1.REF.lancaster.2011.179">Lancaster et al 2011</a>].</p></div></dd></dl></div></div></div></div><div id="ea1.Management"><h2 id="_ea1_Management_">Management</h2><div id="ea1.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and therapeutic needs in an individual diagnosed with episodic ataxia type 1, the evaluations summarized in <a class="figpopup" href="/books/NBK25442/table/ea1.T.recommended_evaluations_following/?report=objectonly" target="object" rid-figpopup="figea1Trecommendedevaluationsfollowing" rid-ob="figobea1Trecommendedevaluationsfollowing">Table 3</a> (if not already completed) are recommended.</p><div id="ea1.T.recommended_evaluations_following" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Episodic Ataxia Type 1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25442/table/ea1.T.recommended_evaluations_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ea1.T.recommended_evaluations_following_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ea1.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_ea1.T.recommended_evaluations_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_ea1.T.recommended_evaluations_following_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic examination</td><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Incl initiation (&#x00026; observation) of attacks by either mild exercise or vestibular stimuli (see <a href="#ea1.Clinical_Description">Clinical Description</a>, <b>Triggers</b>)</td></tr><tr><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Electromyogram</td><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To confirm the presence of myokymia if it is not visible on examination</td></tr><tr><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Electroencephalogram</td><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To evaluate for epilepsy&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_ea1.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ea1.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al [1999]</a>, <a class="bk_pop" href="#ea1.REF.eunson.2000.647">Eunson et al [2000]</a>, <a class="bk_pop" href="#ea1.REF.chen.2007.131">Chen et al [2007]</a></p></div></dd></dl></div></div></div></div><div id="ea1.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="ea1.T.treatment_of_manifestations_in_ind" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Episodic Ataxia Type 1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25442/table/ea1.T.treatment_of_manifestations_in_ind/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ea1.T.treatment_of_manifestations_in_ind_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Typical attacks&#x000a0;<sup>1</sup></b></td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acetazolamide&#x000a0;<sup>2</sup>: 125 mg orally 1x/day starting dose; in those w/good renal function, &#x02191; daily doses may be required: 8-30 mg/kg/day in 1-4 divided doses (max dose: 1 g/day)</td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acetazolamide should not be prescribed to patients w/liver, renal, or adrenal insufficiency.</td></tr><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Phenytoin 3.7 mg/kg/day may improve muscle stiffness &#x00026; motor performance.&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In some cases, phenytoin but not acetazolamide has shown effectiveness for both the ataxia &#x00026; the dyskinesia.&#x000a0;<sup>5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sulthiame 50-200 mg daily may &#x02193; attack rate.</td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">During this treatment abortive attacks lasting a few secs were still observed; troublesome side effects incl paresthesias &#x00026; intermittent carpal spasm.</td></tr><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Carbamazepine has been prescribed in doses up to 1,600 mg/day.&#x000a0;<sup>7</sup></td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Significant &#x02193; in frequency, severity, &#x00026; duration of symptoms observed&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Lamotrigine has been proposed as an alternative treatment.</td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Attacks ameliorated in some patients&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Seizures</b></td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diphenylhydantoin 150-300 mg/day</td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Resulted in reasonable control of seizures in some</td></tr><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Other antiepileptic meds may be required to control seizures in some.&#x000a0;<sup>10</sup></td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to neurologist.</td></tr><tr><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Scoliosis</b></td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Routine treatment per orthopedist</td><td headers="hd_h_ea1.T.treatment_of_manifestations_in_ind_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ea1.TF.4.1"><p class="no_margin">Several drugs variably improve EA1 symptoms, but with the lack of clinical trials comparing the efficacy of these drugs, no single medication has been proven to be very effective.</p></div></dd><dt>2. </dt><dd><div id="ea1.TF.4.2"><p class="no_margin">Chronic treatment with acetazolamide may result in side effects including neuropsychiatric manifestations, tiredness, paresthesias, rash, and formation of renal calculi, necessitating discontinuation of therapy [<a class="bk_pop" href="#ea1.REF.graves.2014.1009">Graves et al 2014</a>, <a class="bk_pop" href="#ea1.REF.dadamo.2015a.525">D'Adamo et al 2015a</a>].</p></div></dd><dt>3. </dt><dd><div id="ea1.TF.4.3"><p class="no_margin"><a class="bk_pop" href="#ea1.REF.kinali.2004.689">Kinali et al [2004]</a></p></div></dd><dt>4. </dt><dd><div id="ea1.TF.4.4"><p class="no_margin">Phenytoin should be used with caution in young patients, as it may cause permanent cerebellar dysfunction and atrophy [<a class="bk_pop" href="#ea1.REF.de_marcos.2003.312">De Marcos et al 2003</a>].</p></div></dd><dt>5. </dt><dd><div id="ea1.TF.4.5"><p class="no_margin"><a class="bk_pop" href="#ea1.REF.dressler.2005.1299">Dressler &#x00026; Benecke [2005]</a></p></div></dd><dt>6. </dt><dd><div id="ea1.TF.4.6"><p class="no_margin">Phenytoin is most often a second-line drug for typical attacks [<a class="bk_pop" href="#ea1.REF.mctague.2018.cd001905">McTague et al 2018</a>].</p></div></dd><dt>7. </dt><dd><div id="ea1.TF.4.7"><p class="no_margin">The dose needs to be adjusted according to factors including age, weight, the particular carbamazepine product being used, responsiveness of the individual, and other medications being taken.</p></div></dd><dt>8. </dt><dd><div id="ea1.TF.4.8"><p class="no_margin"><a class="bk_pop" href="#ea1.REF.imbrici.2017.6">Imbrici et al [2017]</a></p></div></dd><dt>9. </dt><dd><div id="ea1.TF.4.9"><p class="no_margin"><a class="bk_pop" href="#ea1.REF.graves.2014.1009">Graves et al [2014]</a></p></div></dd><dt>10. </dt><dd><div id="ea1.TF.4.10"><p class="no_margin"><a class="bk_pop" href="#ea1.REF.graves.2010.367">Graves et al [2010]</a></p></div></dd></dl></div></div></div><div id="ea1.Developmental_Delay__Intellectual_Di"><h4>Developmental Delay / Intellectual Disability Management Issues</h4><p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a federally funded program available in all states.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed.</p><p><b>Ages 5-21 years</b></p><ul><li class="half_rhythm"><div>In the US, an IEP based on the individual's level of function should be developed by the local public school district. Affected children are permitted to remain in the public school district until age 21.</div></li><li class="half_rhythm"><div>Discussion about transition plans including financial, vocation/employment, and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood.</div></li></ul><p><b>All ages.</b> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life.</p><p>Consideration of private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs is recommended. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p><p>In the US:</p><ul><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div><div id="ea1.Motor_Dysfunction"><h4>Motor Dysfunction</h4><p><b>Gross motor dysfunction.</b> Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation).</p><p><b>Fine motor dysfunction.</b> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.</p></div></div><div id="ea1.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>In addition to the pharmacologic treatments mentioned above, behavioral measures such as avoidance of stress, abrupt movements, loud noises, and caffeine may be implemented to reduce disease manifestations in either a symptomatic or an asymptomatic person.</p></div><div id="ea1.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Contractures occur in a small proportion of individuals and can be prevented by appropriate physiotherapy.</p></div><div id="ea1.Surveillance"><h3>Surveillance</h3><p>Surveillance should include annual neurologic examination.</p></div><div id="ea1.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Known triggers of attacks (see <a href="#ea1.Clinical_Description">Clinical Description</a>, <b>Triggers</b>) should be avoided; physical exertion, emotional stress, and changes in environmental temperature are the most common triggers.</p><p>Marked generalized myokymia has been reported during induction of anesthesia [<a class="bk_pop" href="#ea1.REF.kinali.2004.689">Kinali et al 2004</a>].</p></div><div id="ea1.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic at-risk relatives in order to identify as early as possible those who would benefit from behavioral measures and avoidance of caffeine intake. If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk relatives.</p><p>See <a href="#ea1.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ea1.Pregnancy_Management"><h3>Pregnancy Management</h3><p>No published literature addresses management of the pregnancy of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> mother or the effect of maternal EA1 on a fetus. However, affected women should be made aware that pregnancy may trigger attacks [<a class="bk_pop" href="#ea1.REF.graves.2014.1009">Graves et al 2014</a>] and the possible loss of balance and fall could endanger the fetus's life. Moreover, several stressors that trigger attacks may cause breathing difficulties, thus, delivery by C-section should be considered.</p><p>In general, women with epilepsy or a seizure disorder from any cause are at greater risk for mortality during pregnancy than pregnant women without a seizure disorder; use of antiepileptic medication during pregnancy reduces this risk. However, exposure to antiepileptic medication may increase the risk for adverse fetal outcome (depending on the drug used, the dose, and the stage of pregnancy at which medication is taken). Nevertheless, the risk of an adverse outcome to the fetus from antiepileptic medication exposure is often less than that associated with exposure to an untreated maternal seizure disorder. Therefore, use of antiepileptic medication to treat a maternal seizure disorder during pregnancy is typically recommended. Discussion of the risks and benefits of using a given antiepileptic drug during pregnancy should ideally take place prior to conception. Transitioning to a lower-risk medication prior to pregnancy may be possible [<a class="bk_pop" href="#ea1.REF.sarma.2016.467">Sarma et al 2016</a>].</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="ea1.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="ea1.Other"><h3>Other</h3><p>Morphologic studies on lateral gastrocnemius (LG) muscles derived from a mouse model of EA1 did not reveal changes in muscle mass, fiber type composition, or vascularization [<a class="bk_pop" href="#ea1.REF.brunetti.2012.310">Brunetti et al 2012</a>].</p><p>Homozygous Val408Ala/Val408Ala pathogenic variants are embryonically lethal in an animal model of EA1 [<a class="bk_pop" href="#ea1.REF.herson.2003.378">Herson et al 2003</a>], although this has not been reported in humans.</p></div></div><div id="ea1.Genetic_Counseling"><h2 id="_ea1_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ea1.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Episodic ataxia type 1 (EA1) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="ea1.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with EA1 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with EA1 may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i> pathogenic variant is unknown.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include neurologic evaluation and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>KCNA1</i> pathogenic variant identified in the proband.</div></li><li class="half_rhythm"><div>If the <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent (though theoretically possible, no instances of germline mosaicism have been reported).</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with EA1 may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate neurologic evaluation and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> have been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the pathogenic variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If the <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of the general population (though still &#x0003c;1%) because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, sibs are still at increased risk for EA1 because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with EA1 has a 50% chance of inheriting the <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="ea1.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ea1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></b>. When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk is before pregnancy. Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk of being affected.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ea1.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for EA1 are possible.</p></div></div><div id="ea1.Resources"><h2 id="_ea1_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Ataxia UK</b></div><div>Lincoln House</div><div>1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> 0845 644 0606 (helpline); 020 7582 1444 (office); +44 (0) 20 7582 1444 (from abroad)</div><div><b>Email:</b> helpline@ataxia.org.uk; office@ataxia.org.uk</div><div><a href="http://www.ataxia.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org.uk</a></div></li><li class="half_rhythm"><div><b>euro-ATAXIA (European Federation of Hereditary Ataxias)</b></div><div>Ataxia UK</div><div>Lincoln House, Kennington Park, 1-3 Brixton Road</div><div>London SW9 6DE</div><div>United Kingdom</div><div><b>Phone:</b> +44 (0) 207 582 1444</div><div><b>Email:</b> smillman@ataxia.org.uk</div><div><a href="https://www.euroataxia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.euroataxia.org</a></div></li><li class="half_rhythm"><div><b>National Ataxia Foundation</b></div><div>2600 Fernbrook Lane</div><div>Suite 119</div><div>Minneapolis MN 55447</div><div><b>Phone:</b> 763-553-0020</div><div><b>Email:</b> naf@ataxia.org</div><div><a href="http://www.ataxia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ataxia.org</a></div></li><li class="half_rhythm"><div><b>CoRDS Registry</b></div><div>Sanford Research</div><div>2301 East 60th Street North</div><div>Sioux Falls SD 57104</div><div><b>Phone:</b> 605-312-6423</div><div><b>Email:</b> sanfordresearch@sanfordhealth.org</div><div><a href="http://www.sanfordresearch.org/SpecialPrograms/cords/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CoRDS Registry</a></div></li></ul></div><div id="ea1.Molecular_Genetics"><h2 id="_ea1_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ea1.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Episodic Ataxia Type 1: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25442/table/ea1.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ea1.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ea1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ea1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ea1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ea1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ea1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ea1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ea1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3736" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>KCNA1</i></a></td><td headers="hd_b_ea1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3736" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">12p13<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_ea1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q09470" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Potassium voltage-gated channel subfamily A member 1</a></td><td headers="hd_b_ea1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/KCNA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNA1 database</a></td><td headers="hd_b_ea1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KCNA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNA1</a></td><td headers="hd_b_ea1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNA1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">KCNA1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ea1.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ea1.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Episodic Ataxia Type 1 (<a href="/omim/160120,176260" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25442/table/ea1.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ea1.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/160120" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">160120</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EPISODIC ATAXIA, TYPE 1; EA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176260" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176260</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 1; KCNA1</td></tr></tbody></table></div></div><div id="ea1.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>KCNA1</i> encodes the potassium voltage-gated channel subfamily A member 1, commonly known as the &#x003b1;-subunit of the voltage-gated delayed-rectifier potassium channel Kv1.1. Voltage-gated potassium channels (Kv) play key roles in neurotransmission and nerve cell physiology. They shorten the duration of action potentials, modulate the release of neurotransmitters, and control the excitability, electrical properties, and firing pattern of central and peripheral neurons [<a class="bk_pop" href="#ea1.REF.pessia.2004">Pessia 2004</a>]. In particular, Kv1.1 channels regulate neuromuscular transmission and control the release of &#x003b2;-aminobutyric acid (GABA) from cerebellar basket cells onto Purkinje cells [<a class="bk_pop" href="#ea1.REF.herson.2003.378">Herson et al 2003</a>]. The Kv1.1 channel opens upon membrane depolarization, after which potassium flow results in a hyperpolarizing effect that is necessary to limit neuronal excitability [<a class="bk_pop" href="#ea1.REF.pessia.2004">Pessia 2004</a>]. The channel is known for its role in controlling the excitability of cerebellar, hippocampal, cortical, and peripheral nervous system neurons [<a class="bk_pop" href="#ea1.REF.brunetti.2012.310">Brunetti et al 2012</a>, <a class="bk_pop" href="#ea1.REF.dadamo.2015a.525">D'Adamo et al 2015a</a>].</p><p>Functional studies have shown that pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>KCNA1</i> (the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> currently known to be associated with EA1) result in loss of function of the channel. Kv1.1 channel function in EA1 is impaired by altering the channel's gating kinetics, voltage dependence, assembly, and trafficking [<a class="bk_pop" href="#ea1.REF.imbrici.2006.3073">Imbrici et al 2006</a>, <a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al 2017</a>; for a review see <a class="bk_pop" href="#ea1.REF.dadamo.2015b.317">D'Adamo et al 2015b</a>].</p><p>Homomeric Kv1.1 channels are tetrameric structures composed of four identical &#x003b1;-subunit monomers. Each monomer is encoded by <i>KCNA1</i>. However, potassium channel diversity is greatly enhanced by the ability of Kv1.1 to co-assemble with &#x003b1;-subunits of other members of the Kv1 family to form heterotetrameric channels with properties different from the parental homomeric channels. Kv1.1 is mostly found co-assembled with Kv1.2 subunits; they are expressed together at cerebellar basket cell terminals and at the juxtaparanodal region of motor axons. A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in Kv1.1 affects the function of the Kv1.1/1.2 heteromeric channel to which they contribute [<a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al 2017</a>]. D'Adamo et al first demonstrated that proteins encoded by <i>KCNA1</i> pathogenic variants associated with EA1 alter the expression and gating properties of heteromeric channels composed of human Kv1.2 and Kv1.1 subunits [<a class="bk_pop" href="#ea1.REF.dadamo.1999.1335">D'Adamo et al 1999</a>, <a class="bk_pop" href="#ea1.REF.rea.2002.5">Rea et al 2002</a>].</p><p>Kv1.1 channels possess a slow process of inactivation, which has been named C-type or P-type depending on the structural determinants of this process that have been located within the C-terminus and pore region. Kv channels may also exhibit fast <i>N-type</i> inactivation that is caused by a "ball-and-chain" mechanism of pore occlusion. Fast inactivation may be conferred to non-<a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> channels by auxiliary subunits such as Kv&#x003b2;1.1 and Kv&#x003b2;1.2. Four &#x003b2; subunits participate in the ion channel complex and provide four inactivation particles; notable example: channels composed of Kv1.1, Kv1.4, and Kv&#x003b2;1.1 subunits that are expressed in hippocampal mossy fiber boutons [<a class="bk_pop" href="#ea1.REF.geiger.2000.927">Geiger &#x00026; Jonas 2000</a>]. Proteins encoded by <i>KCNA1</i> pathogenic variants also impair the function of hetero-oligomeric complexes comprising Kv1.1, Kv1.4, and Kv&#x003b2;1.x subunits in distinct ways [<a class="bk_pop" href="#ea1.REF.imbrici.2006.3073">Imbrici et al 2006</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2011.c1314">Imbrici et al 2011</a>]. These studies raised the question as to whether other allelic variations, whose <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> products may or may not form hetero-oligomeric complexes with Kv1.1 subunits, may underlie a similar channelopathy.</p><p><b>Gene structure.</b>
<i>KCNA1</i> has a transcript of 7,983 nucleotides with a <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of 1,488. There are two exons, but the coding region is located entirely within <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2. The reference sequences in <a class="figpopup" href="/books/NBK25442/table/ea1.T.kcna1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figea1Tkcna1pathogenicvariantsdiscusse" rid-ob="figobea1Tkcna1pathogenicvariantsdiscusse">Table 5</a> include the correction of a sequence error (see <a class="figpopup" href="/books/NBK25442/table/ea1.T.kcna1_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figea1Tkcna1pathogenicvariantsdiscusse" rid-ob="figobea1Tkcna1pathogenicvariantsdiscusse">Table 5</a>, footnote 1). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK25442/#ea1.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> In 5% of control chromosomes analyzed by <a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al [1999]</a>, two silent changes in the coding sequence were observed.</p><p><b>Pathogenic variants.</b> To date, more than 30 <i>KCNA1</i> pathogenic variants have been identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> (see <a class="figpopup" href="/books/NBK25442/figure/ea1.F1/?report=objectonly" target="object" rid-figpopup="figea1F1" rid-ob="figobea1F1">Figure 1</a>). Most are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that are distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>; however, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants and small deletions have also been identified [<a class="bk_pop" href="#ea1.REF.eunson.2000.647">Eunson et al 2000</a>, <a class="bk_pop" href="#ea1.REF.shook.2008.399">Shook et al 2008</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figea1F1" co-legend-rid="figlgndea1F1"><a href="/books/NBK25442/figure/ea1.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figea1F1" rid-ob="figobea1F1"><img class="small-thumb" src="/books/NBK25442/bin/ea1-Image001.gif" src-large="/books/NBK25442/bin/ea1-Image001.jpg" alt="Figure 1. . Schematic drawing of the conventional membrane topology of a human Kv1." /></a><div class="icnblk_cntnt" id="figlgndea1F1"><h4 id="ea1.F1"><a href="/books/NBK25442/figure/ea1.F1/?report=objectonly" target="object" rid-ob="figobea1F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Schematic drawing of the conventional membrane topology of a human Kv1.1 subunit. Four such subunits comprise a functional homotetrameric channel. Different subunits belonging to the Kv1 subfamily may form heterotetrameric channels. The positions of pathogenic <a href="/books/NBK25442/figure/ea1.F1/?report=objectonly" target="object" rid-ob="figobea1F1">(more...)</a></p></div></div><p>Interestingly, four different variants of the highly conserved threonine 226 residue, located within the second transmembrane segment, have been identified [<a class="bk_pop" href="#ea1.REF.rajakulendran.2007.258">Rajakulendran et al 2007</a>]. In particular, the amino acid change p.Thr226Arg is associated with epilepsy, infantile contractures, postural abnormalities, and skeletal deformities. Although the defects caused by the p.Thr226Ala, p.Thr226Arg, and p.Thr226Met amino acid changes on channel functions are virtually identical, they lead to diverse phenotypes.</p><div id="ea1.T.kcna1_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>KCNA1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK25442/table/ea1.T.kcna1_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ea1.T.kcna1_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.676A&#x0003e;G</td><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr226Ala</td><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000217.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000217<wbr style="display:inline-block"></wbr>​.2</a>&#x000a0;<sup>1</sup><br /><a href="/protein/NP_000208.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000208<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.677C&#x0003e;G</td><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr226Arg</td></tr><tr><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.677C&#x0003e;T</td><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr226Met</td></tr><tr><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1223T&#x0003e;C</td><td headers="hd_h_ea1.T.kcna1_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val408Ala</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="ea1.TF.5.1"><p class="no_margin">Reference sequences include the correction of a sequence error published by <a class="bk_pop" href="#ea1.REF.ramaswami.1990.214">Ramaswami et al [1990]</a> and reported by <a class="bk_pop" href="#ea1.REF.browne.1994.136">Browne et al [1994]</a> and <a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al [1999]</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>KCNA1</i> encodes the voltage-gated K<sup>+</sup> channel Kv1.1. The predicted 496-amino-acid Kv1.1 protein contains six hydrophobic segments with the N- and C-termini residing inside the cell. The S4 segment of each Kv1.1 subunit comprises the main voltage sensor that opens the channel by undergoing a conformational rearrangement on membrane depolarization. The S5-S6 loop (H5 region) contributes to the ion-conducting pore. The GYG residues, residing within this loop, control the K<sup>+</sup> selectivity of the channel.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The molecular mechanisms underlying episodic ataxia type 1 have been established by determining the functional properties of wild type and several mutant channels in <i>Xenopus</i> oocytes or mammalian cell lines [<a class="bk_pop" href="#ea1.REF.adelman.1995.1449">Adelman et al 1995</a>, <a class="bk_pop" href="#ea1.REF.dadamo.1998.1200">D'Adamo et al 1998</a>, <a class="bk_pop" href="#ea1.REF.zerr.1998.2842">Zerr et al 1998</a>, <a class="bk_pop" href="#ea1.REF.dadamo.1999.1335">D'Adamo et al 1999</a>, <a class="bk_pop" href="#ea1.REF.zuberi.1999.817">Zuberi et al 1999</a>, <a class="bk_pop" href="#ea1.REF.eunson.2000.647">Eunson et al 2000</a>, <a class="bk_pop" href="#ea1.REF.manganas.2001.49427">Manganas et al 2001</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2003.373">Imbrici et al 2003</a>, <a class="bk_pop" href="#ea1.REF.cusimano.2004.237">Cusimano et al 2004</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2006.3073">Imbrici et al 2006</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2007.c778">Imbrici et al 2007</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2008.577">Imbrici et al 2008</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2009.39">Imbrici et al 2009</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2011.c1314">Imbrici et al 2011</a>, <a class="bk_pop" href="#ea1.REF.dadamo.2015a.525">D'Adamo et al 2015a</a>]. Overall, these studies have shown that allelic variations underlying EA1 impair channel function and reduce the outward K<sup>+</sup> flux through the channel, although with highly variable effects on aspects of channel expression and gating.</p><p>Regarding channel gating, <i>KCNA1</i> pathogenic variants may alter the protein structure and affect the kinetics of opening and closing, voltage dependence, and N- and C-type inactivation [<a class="bk_pop" href="#ea1.REF.dadamo.1998.1200">D'Adamo et al 1998</a>, <a class="bk_pop" href="#ea1.REF.dadamo.1999.1335">D'Adamo et al 1999</a>, <a class="bk_pop" href="#ea1.REF.maylie.2002.4786">Maylie et al 2002</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2006.3073">Imbrici et al 2006</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2009.39">Imbrici et al 2009</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2011.c1314">Imbrici et al 2011</a>, <a class="bk_pop" href="#ea1.REF.dadamo.2015b.317">D'Adamo et al 2015b</a>, <a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al 2017</a>].</p><p>Individuals with EA1 are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>KCNA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, possessing a normal and a mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, which may be equally expressed. Therefore, channels composed of wild type and mutated subunits may be formed. Co-expression systems, which mimic the heterozygous condition, have shown that some mutated subunits exert dominant negative effects on wild type subunits, resulting in less than half the normal current, whereas others have virtually no effect on surface expression. It has been shown that <i>KCNA1</i> allelic variations also alter the function of heteromeric channels containing different subunits, demonstrating that pathogenic variants in a single <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> disrupt the functions of other closely related proteins [<a class="bk_pop" href="#ea1.REF.dadamo.1999.1335">D'Adamo et al 1999</a>, <a class="bk_pop" href="#ea1.REF.rea.2002.5">Rea et al 2002</a>, <a class="bk_pop" href="#ea1.REF.imbrici.2006.3073">Imbrici et al 2006</a>, <a class="bk_pop" href="#ea1.REF.hasan.2017.4583">Hasan et al 2017</a>]. Based on these findings, a model accounting for the cerebellar symptoms of EA1 was proposed by D'Adamo and colleagues (see <a class="figpopup" href="/books/NBK25442/figure/ea1.F2/?report=objectonly" target="object" rid-figpopup="figea1F2" rid-ob="figobea1F2">Figure 2</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figea1F2" co-legend-rid="figlgndea1F2"><a href="/books/NBK25442/figure/ea1.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figea1F2" rid-ob="figobea1F2"><img class="small-thumb" src="/books/NBK25442/bin/ea1-Image002.gif" src-large="/books/NBK25442/bin/ea1-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndea1F2"><h4 id="ea1.F2"><a href="/books/NBK25442/figure/ea1.F2/?report=objectonly" target="object" rid-ob="figobea1F2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Proposed effects of EA1-causing pathogenic variants on basket cell and Purkinje cell inhibitory outputs The diagram shows a basket cell that has synapses on the initial segment and soma of a number of Purkinje cells from the cerebellar cortex of an unaffected <a href="/books/NBK25442/figure/ea1.F2/?report=objectonly" target="object" rid-ob="figobea1F2">(more...)</a></p></div></div><p>A mouse model of EA1 has been generated by introducing a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> analogous to the human p.Val408Ala EA1 pathogenic variant into the murine ortholog, <i>Kcna1.</i> These animals showed impaired motor performance and altered cerebellar GABAergic transmission from the basket cells to the Purkinje cells [<a class="bk_pop" href="#ea1.REF.herson.2003.378">Herson et al 2003</a>]. Such <i>Kv1.1</i> knock-in ataxic mice also exhibited spontaneous myokymic activity exacerbated by fatigue, ischemia, and low temperature [<a class="bk_pop" href="#ea1.REF.brunetti.2012.310">Brunetti et al 2012</a>]. Spontaneous myokymic discharges were present despite motor nerve axotomy, suggesting that the motor nerve is an important generator of myokymic activity. This study also showed that altered Ca<sup>2+</sup> homeostasis in motor axons of mutated animals may contribute to spontaneous myokymic activity [<a class="bk_pop" href="#ea1.REF.brunetti.2012.310">Brunetti et al 2012</a>].</p><p>The causes that trigger the paroxysms of ataxia remain elusive, although a phenomenon akin to spreading acidification of the cerebellar cortex has been suggested [<a class="bk_pop" href="#ea1.REF.chen.2005.1287">Chen et al 2005</a>].</p></div></div><div id="ea1.References"><h2 id="_ea1_References_">References</h2><div id="ea1.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.adelman.1995.1449">Adelman JP, Bond CT, Pessia M, Maylie J. Episodic ataxia results from voltage-dependent potassium channels with altered functions. <span><span class="ref-journal">Neuron. </span>1995;<span class="ref-vol">15</span>:1449–54.</span> [<a href="/pubmed/8845167" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8845167</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.browne.1994.136">Browne DL, Gancher ST, Nutt JG, Brunt ER, Smith EA, Kramer P, Litt M. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. <span><span class="ref-journal">Nat Genet. </span>1994;<span class="ref-vol">8</span>:136–40.</span> [<a href="/pubmed/7842011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7842011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.brownstein.2016.11">Brownstein CA, Beggs AH, Rodan L, Shi J, Towne MC, Pelletier R, Cao S, Rosenberg PA, Urion DK, Picker J, Tan WH, Agrawal PB. Clinical heterogeneity associated with KCNA1 mutations include cataplexy and nonataxic presentations. <span><span class="ref-journal">Neurogenetics. </span>2016;<span class="ref-vol">17</span>:11–6.</span> [<a href="/pmc/articles/PMC4911217/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4911217</span></a>] [<a href="/pubmed/26395884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26395884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.brunetti.2012.310">Brunetti O, Imbrici P, Botti FM, Pettorossi VE, D'Adamo MC, Valentino M, Zammit C, Mora M, Gibertini S, Di Giovanni G, Muscat R, Pessia M. Kv1.1 knock-in ataxic mice exhibit spontaneous myokymic activity exacerbated by fatigue, ischemia and low temperature. <span><span class="ref-journal">Neurobiol Dis. </span>2012;<span class="ref-vol">47</span>:310–21.</span> [<a href="/pmc/articles/PMC3402927/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3402927</span></a>] [<a href="/pubmed/22609489" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22609489</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.chen.2005.1287">Chen G, Gao W, Reinert KC, Popa LS, Hendrix CM, Ross ME, Ebner TJ. Involvement of Kv1 potassium channels in spreading acidification and depression in the cerebellar cortex. <span><span class="ref-journal">J Neurophysiol. </span>2005;<span class="ref-vol">94</span>:1287–98.</span> [<a href="/pubmed/15843481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15843481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.chen.2007.131">Chen H, von Hehn C, Kaczmarek LK, Ment LR, Pober BR, Hisama FM. Functional analysis of a novel potassium channel (KCNA1) mutation in hereditary myokymia. <span><span class="ref-journal">Neurogenetics. </span>2007;<span class="ref-vol">8</span>:131–5.</span> [<a href="/pmc/articles/PMC1820748/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1820748</span></a>] [<a href="/pubmed/17136396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17136396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.conroy.2014.505">Conroy J, McGettigan P, Murphy R, Webb D, Murphy SM, McCoy B, Albertyn C, McCreary D, McDonagh C, Walsh O, Lynch S, Ennis S. A novel locus for episodic ataxia: UBR4 the likely candidate. <span><span class="ref-journal">Eur J Hum Genet. </span>2014;<span class="ref-vol">22</span>:505–10.</span> [<a href="/pmc/articles/PMC3953901/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3953901</span></a>] [<a href="/pubmed/23982692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23982692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.cusimano.2004.237">Cusimano A, D'Adamo MC, Pessia M. An episodic ataxia type-1 mutation in the S1 segment sensitises the hKv1.1 potassium channel to extracellular Zn2+. <span><span class="ref-journal">FEBS Lett. </span>2004;<span class="ref-vol">576</span>:237–44.</span> [<a href="/pubmed/15474044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15474044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.dadamo.2015a.525">D'Adamo MC, Gallenm&#x000fc;ller C, Servettini I, Hartl E, Tucker SJ, Arning L, Biskup S, Grottesi A, Guglielmi L, Imbrici P, Bernasconi P, Di Giovanni G, Franciolini F, Catacuzzeno L, Pessia M, Klopstock T. Novel phenotype associated with a mutation in the KCNA1(Kv1.1) gene. <span><span class="ref-journal">Front Physiol. </span>2015a;<span class="ref-vol">5</span>:525.</span> [<a href="/pmc/articles/PMC4295438/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4295438</span></a>] [<a href="/pubmed/25642194" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25642194</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.dadamo.2015b.317">D'Adamo MC, Hasan S, Guglielmi L, Servettini I, Cenciarini M, Catacuzzeno L, Franciolini F. New insights into the pathogenesis and therapeutics of episodic ataxia type 1. <span><span class="ref-journal">Front Cell Neurosci. </span>2015b;<span class="ref-vol">9</span>:317.</span> [<a href="/pmc/articles/PMC4541215/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4541215</span></a>] [<a href="/pubmed/26347608" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26347608</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.dadamo.2012">D'Adamo MC, Imbrici P, Di Giovanni G, Pessia M. The neurobiology of episodic ataxia type 1: a Shaker-like K+ channel disorder. In: Hong SH, ed. <em>Ataxia: Causes, Symptoms and Treatment.</em> New York, NY: Nova Science Publishers; 2012:47-75.</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.dadamo.1999.1335">D'Adamo MC, Imbrici P, Sponcichetti F, Pessia M. Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K(+) channel function. <span><span class="ref-journal">FASEB J. </span>1999;<span class="ref-vol">13</span>:1335–45.</span> [<a href="/pubmed/10428758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10428758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.dadamo.1998.1200">D'Adamo MC, Liu Z, Adelman JP, Maylie J, Pessia M. Episodic ataxia type-1 mutations in the hKv1.1 cytoplasmic pore region alter the gating properties of the channel. <span><span class="ref-journal">EMBO J. </span>1998;<span class="ref-vol">17</span>:1200–7.</span> [<a href="/pmc/articles/PMC1170468/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1170468</span></a>] [<a href="/pubmed/9482717" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9482717</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.damji.1996.338">Damji KF, Allingham RR, Pollock SC, Small K, Lewis KE, Stajich JM, Yamaoka LH, Vance JM, Pericak-Vance MA. Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. <span><span class="ref-journal">Arch Neurol. </span>1996;<span class="ref-vol">53</span>:338–44.</span> [<a href="/pubmed/8929156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8929156</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.de_marcos.2003.312">De Marcos FA, Ghizoni E, Kobayashi E, Li LM, Cendes F. Cerebellar volume and long-term use of phenytoin. <span><span class="ref-journal">Seizure. </span>2003;<span class="ref-vol">12</span>:312–5.</span> [<a href="/pubmed/12810345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12810345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.demos.2009.778">Demos MK, Macri V, Farrell K, Nelson TN, Chapman K, Accili E, Armstrong L. A novel KCNA1 mutation associated with global delay and persistent cerebellar dysfunction. <span><span class="ref-journal">Mov Disord. </span>2009;<span class="ref-vol">24</span>:778–82.</span> [<a href="/pubmed/19205071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19205071</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.de_vries.2009.97">de Vries B, Mamsa H, Stam AH, Wan J, Bakker SLM, Vanmolkot KRJ, Haan J, Terwindt GM, Boon EMJ, Howard BD, Frants RR, Baloh RW, Ferrari MD, Jen JC, van den Maagdenberg AMJM. Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake. <span><span class="ref-journal">Arch Neurol. </span>2009;<span class="ref-vol">66</span>:97–101.</span> [<a href="/pubmed/19139306" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19139306</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.dressler.2005.1299">Dressler D, Benecke R. Diagnosis and management of acute movement disorders. <span><span class="ref-journal">J Neurol. </span>2005;<span class="ref-vol">252</span>:1299–306.</span> [<a href="/pubmed/16208529" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16208529</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.escayg.2000.1531">Escayg A, De Waard M, Lee DD, Bichet D, Wolf P, Mayer T, Johnston J, Baloh R, Sander T, Meisler MH. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">66</span>:1531–9.</span> [<a href="/pmc/articles/PMC1378014/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1378014</span></a>] [<a href="/pubmed/10762541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10762541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.eunson.2000.647">Eunson LH, Rea R, Zuberi SM, Youroukos S, Panayiotopoulos CP, Liguori R, Avoni P, McWilliam RC, Stephenson JB, Hanna MG, Kullmann DM, Spauschus A. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. <span><span class="ref-journal">Ann Neurol. </span>2000;<span class="ref-vol">48</span>:647–56.</span> [<a href="/pubmed/11026449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11026449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.farmer.1963.471">Farmer TW, Mustian VM. Vestibulo-cerebellar ataxia: a newly defined hereditary syndrome with periodic manifestations. <span><span class="ref-journal">Arch Neurol. </span>1963;<span class="ref-vol">8</span>:471–80.</span> [<a href="/pubmed/13944410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13944410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.geiger.2000.927">Geiger JR, Jonas P. Dynamic control of presynaptic Ca(2+) inflow by fast-inactivating K(+) channels in hippocampal mossy fiber boutons. <span><span class="ref-journal">Neuron. </span>2000;<span class="ref-vol">28</span>:927–39.</span> [<a href="/pubmed/11163277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11163277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.glaudemans.2009.936">Glaudemans B, van der Wijst J, Scola RH, Lorenzoni PJ, Heister A, van der Kemp AW, Knoers NV, Hoenderop JG, Bindels RJ. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:936–42.</span> [<a href="/pmc/articles/PMC2662556/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2662556</span></a>] [<a href="/pubmed/19307729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19307729</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.graves.2014.1009">Graves TD, Cha YH, Hahn AF, Barohn R, Salajegheh MK, Griggs RC, Bundy BN, Jen JC, Baloh RW, Hanna MG. CINCH Investigators. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. <span><span class="ref-journal">Brain. </span>2014;<span class="ref-vol">137</span>:1009–18.</span> [<a href="/pmc/articles/PMC3959554/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3959554</span></a>] [<a href="/pubmed/24578548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24578548</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.graves.2010.367">Graves TD, Rajakulendran S, Zuberi SM, Morris HR, Schorge S, Hanna MG, Kullmann DM. Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">75</span>:367–72.</span> [<a href="/pmc/articles/PMC2918890/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2918890</span></a>] [<a href="/pubmed/20660867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20660867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.hart.2002.1887">Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. <span><span class="ref-journal">Brain. </span>2002;<span class="ref-vol">125</span>:1887–95.</span> [<a href="/pubmed/12135978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12135978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.hasan.2017.4583">Hasan S, Bove C, Silvestri G, Mantuano E, Modoni A, Veneziano L, Macchioni L, Hunter T, Hunter G, Pessia M, D'Adamo MC. A channelopathy mutation in the voltage-sensor discloses contributions of a conserved phenylalanine to gating properties of Kv1.1 channels and ataxia. <span><span class="ref-journal">Sci Rep. </span>2017;<span class="ref-vol">7</span>:4583.</span> [<a href="/pmc/articles/PMC5496848/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5496848</span></a>] [<a href="/pubmed/28676720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28676720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.herson.2003.378">Herson PS, Virk M, Rustay NR, Bond CT, Crabbe JC, Adelman JP, Maylie J. A mouse model of episodic ataxia type-1. <span><span class="ref-journal">Nat Neurosci. </span>2003;<span class="ref-vol">6</span>:378–83.</span> [<a href="/pubmed/12612586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12612586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.imbrici.2017.6">Imbrici P, Altamura C, Gualandi F, Mangiatordi GF, Neri M, De Maria G, Ferlini A, Padovani A, D'Adamo MC, Nicolotti O, Pessia M, Conte D, Filosto M, Desaphy JF. <span><span class="ref-journal">Mol Cell Neurosci. </span>2017;<span class="ref-vol">83</span>:6–12. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28666963" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">A novel KCNA1 mutation in a patient with paroxysmal ataxia, myokymia, painful contractures and metabolic dysfunctions.</a></span> [<a href="/pubmed/28666963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28666963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.imbrici.2003.373">Imbrici P, Cusimano A, D'Adamo MC, De Curtis A, Pessia M. Functional characterization of an episodic ataxia type-1 mutation occurring in the S1 segment of hKv1.1 channels. <span><span class="ref-journal">Pflugers Arch. </span>2003;<span class="ref-vol">446</span>:373–9.</span> [<a href="/pubmed/12799903" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12799903</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.imbrici.2007.c778">Imbrici P, D'Adamo MC, Cusimano A, Pessia M. Episodic ataxia type 1 mutation F184C alters Zn2+-induced modulation of the human K+ channel Kv1.4-Kv1.1/Kvbeta1.1. <span><span class="ref-journal">Am J Physiol Cell Physiol. </span>2007;<span class="ref-vol">292</span>:C778–87.</span> [<a href="/pubmed/16956965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16956965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.imbrici.2011.c1314">Imbrici P, D'Adamo MC, Grottesi A, Biscarini A, Pessia M. Episodic ataxia type 1 mutations affect fast inactivation of K<sup>+</sup> channels by a reduction in either subunit surface expression or affinity for inactivation domain. <span><span class="ref-journal">Am J Physiol Cell Physiol. </span>2011;<span class="ref-vol">300</span>:C1314–22.</span> [<a href="/pubmed/21307345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21307345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.imbrici.2006.3073">Imbrici P, D'Adamo MC, Kullmann DM, Pessia M. Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human K+ channels Kv1.4-1.1/Kvbeta1.1 and Kv1.4-1.1/Kvbeta1.2. <span><span class="ref-journal">Eur J Neurosci. </span>2006;<span class="ref-vol">24</span>:3073–83.</span> [<a href="/pubmed/17156368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17156368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.imbrici.2009.39">Imbrici P, Grottesi A, D'Adamo MC, Mannucci R, Tucker S, Pessia M. Contributions of the central hydrophobic residue in the PXP motif of voltage-dependent K+ channels to S6 flexibility and gating properties. <span><span class="ref-journal">Channels (Austin). </span>2009;<span class="ref-vol">3</span>:39–45.</span> [<a href="/pubmed/19202350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19202350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.imbrici.2008.577">Imbrici P, Gualandi F, D'Adamo MC, Taddei Masieri M, Cudia P, De Grandis D, Mannucci R, Nicoletti I, Tucker SJ, Ferlini A, Pessia M. A novel KCNA1 mutation identified in an Italian family affected by episodic ataxia type 1. <span><span class="ref-journal">Neuroscience. </span>2008;<span class="ref-vol">157</span>:577–87.</span> [<a href="/pubmed/18926884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18926884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.irani.2010.2734">Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A. Antibodies to Kv1 potassium channel-complex proteins leucine-rich glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis Morvan's syndrome and acquired neuromyotonia. <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>:2734–48.</span> [<a href="/pmc/articles/PMC2929337/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2929337</span></a>] [<a href="/pubmed/20663977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20663977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.jen.2005.529">Jen JC, Wan J, Palos TP, Howard BD, Baloh RW. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:529–34.</span> [<a href="/pubmed/16116111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16116111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.kerber.2007.749">Kerber KA, Jen JC, Lee H, Nelson SF, Baloh RW. A new episodic ataxia syndrome with linkage to chromosome 19q13. <span><span class="ref-journal">Arch Neurol. </span>2007;<span class="ref-vol">64</span>:749–52.</span> [<a href="/pubmed/17502476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17502476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.kiernan.2000.399">Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. <span><span class="ref-journal">Muscle Nerve. </span>2000;<span class="ref-vol">23</span>:399–409.</span> [<a href="/pubmed/10679717" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10679717</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.kinali.2004.689">Kinali M, Jungbluth H, Eunson LH, Sewry CA, Manzur AY, Mercuri E, Hanna MG, Muntoni F. Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. <span><span class="ref-journal">Neuromuscul Disord. </span>2004;<span class="ref-vol">14</span>:689–93.</span> [<a href="/pubmed/15351427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15351427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.klein.2004.147">Klein A, Boltshauser E, Jen J, Baloh RW. Episodic ataxia type 1 with distal weakness: a novel manifestation of a potassium channelopathy. <span><span class="ref-journal">Neuropediatrics. </span>2004;<span class="ref-vol">35</span>:147–9.</span> [<a href="/pubmed/15127317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15127317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.lai.2010.776">Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. <span><span class="ref-journal">Lancet Neurol. </span>2010;<span class="ref-vol">9</span>:776–85.</span> [<a href="/pmc/articles/PMC3086669/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3086669</span></a>] [<a href="/pubmed/20580615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20580615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.lancaster.2011.179">Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. <span><span class="ref-journal">Neurology. </span>2011;<span class="ref-vol">77</span>:179–89.</span> [<a href="/pmc/articles/PMC3140073/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3140073</span></a>] [<a href="/pubmed/21747075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21747075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.lee.2004a.536">Lee H, Wang H, Jen JC, Sabatti C, Baloh RW, Nelson SF. A novel mutation in KCNA1 causes episodic ataxia without myokymia. <span><span class="ref-journal">Hum Mutat. </span>2004a;<span class="ref-vol">24</span>:536–42.</span> [<a href="/pubmed/15532032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15532032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.lee.2004b.3161">Lee HY, Xu Y, Huang Y, Ahn AH, Auburger GW, Pandolfo M, Kwiecinski H, Grimes DA, Lang AE, Nielsen JE, Averyanov Y, Servidei S, Friedman A, Van Bogaert P, Abramowicz MJ, Bruno MK, Sorensen BF, Tang L, Fu YH, Pt&#x000e1;cek LJ. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. <span><span class="ref-journal">Hum Mol Genet. </span>2004b;<span class="ref-vol">13</span>:3161–70.</span> [<a href="/pubmed/15496428" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15496428</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.manganas.2001.49427">Manganas LN, Akhtar S, Antonucci DE, Campomanes CR, Dolly JO, Trimmer JS. Episodic ataxia type-1 mutations in the Kv1.1 potassium channel display distinct folding and intracellular trafficking properties. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:49427–34.</span> [<a href="/pubmed/11679591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11679591</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.maylie.2002.4786">Maylie B, Bissonnette E, Virk M, Adelman JP, Maylie JG. Episodic ataxia type 1 mutations in the human Kv1.1 potassium channel alter hKvbeta 1-induced N-type inactivation. <span><span class="ref-journal">J Neurosci. </span>2002;<span class="ref-vol">22</span>:4786–93.</span> [<a href="/pmc/articles/PMC6757728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6757728</span></a>] [<a href="/pubmed/12077175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12077175</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.mctague.2018.cd001905">McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. <span><span class="ref-journal">Cochrane Database Syst Rev. </span>2018;<span class="ref-vol">1</span>:CD001905.</span> [<a href="/pmc/articles/PMC6491279/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6491279</span></a>] [<a href="/pubmed/29320603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29320603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.mestre.2016.245">Mestre TA, Manole A, MacDonald H, Riazi S, Kraeva N, Hanna MG, Lang AE, M&#x000e4;nnikk&#x000f6; R, Yoon G. A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <span><span class="ref-journal">Neurogenetics. </span>2016;<span class="ref-vol">17</span>:245–9.</span> [<a href="/pubmed/27271339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27271339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.pessia.2004">Pessia M. Ion channels and electrical activity. In: Wayne Davies R, Morris BJ, eds. <em>Molecular Biology of the Neuron.</em> Oxford, UK: Oxford University Press; 2004:103-37.</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.rajakulendran.2007.258">Rajakulendran S, Schorge S, Kullmann DM, Hanna MG. Episodic ataxia type 1: a neuronal potassium channelopathy. <span><span class="ref-journal">Neurotherapeutics. </span>2007;<span class="ref-vol">4</span>:258–66.</span> [<a href="/pubmed/17395136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17395136</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.ramaswami.1990.214">Ramaswami M, Gautam M, Kamb A, Rudy B, Tanauye MA, Mathew MK. Human potassium channel genes: molecular cloning and functional expression. <span><span class="ref-journal">Mol Cell Neurosci. </span>1990;<span class="ref-vol">1</span>:214–23.</span> [<a href="/pubmed/19912772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19912772</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.rea.2002.5">Rea R, Spauschus A, Eunson L, Hanna MG, Kullmann DM. Variable K+ channel subunit dysfunction in inherited mutations of KCNA1. <span><span class="ref-journal">J Physiol. </span>2002;<span class="ref-vol">538</span>:5–23.</span> [<a href="/pmc/articles/PMC2290030/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2290030</span></a>] [<a href="/pubmed/11773313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11773313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.rogers.2018.1748">Rogers A, Golumbek P, Cellini E, Doccini V, Guerrini R, Wallgren-Pettersson C, Thuresson AC, Gurnett CA. De novo KCNA1 variants in the PVP motif cause infantile epileptic encephalopathy and cognitive impairment similar to recurrent KCNA2 variants. <span><span class="ref-journal">Am J Med Genet A. </span>2018;<span class="ref-vol">176</span>:1748–52.</span> [<a href="/pubmed/30055040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30055040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.sarma.2016.467">Sarma AK, Khandker N, Kurczewski L, Brophy GM. Medical management of epileptic seizures: challenges and solutions. <span><span class="ref-journal">Neuropsychiatr Dis Treat. </span>2016;<span class="ref-vol">12</span>:467–85.</span> [<a href="/pmc/articles/PMC4771397/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4771397</span></a>] [<a href="/pubmed/26966367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26966367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.set.2017.784">Set KK, Ghosh D, Huq AHM, Luat AF. Episodic ataxia type 1 (K-channelopathy) manifesting as paroxysmal nonkinesogenic dyskinesia: expanding the phenotype. <span><span class="ref-journal">Mov Disord Clin Pract. </span>2017;<span class="ref-vol">4</span>:784–6.</span> [<a href="/pmc/articles/PMC6174441/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6174441</span></a>] [<a href="/pubmed/30363417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30363417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.shook.2008.399">Shook SJ, Mamsa H, Jen JC, Baloh RW, Zhou L. Novel mutation in KCNA1 causes episodic ataxia with paroxysmal dyspnea. <span><span class="ref-journal">Muscle Nerve. </span>2008;<span class="ref-vol">37</span>:399–402.</span> [<a href="/pubmed/17912752" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17912752</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.steckley.2001.1499">Steckley JL, Ebers GC, Cader MZ, McLachlan RS. An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:1499–502.</span> [<a href="/pubmed/11673600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11673600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.tacik.2015.366">Tacik P, Guthrie KJ, Strongosky AJ, Broderick DF, Riegert-Johnson DL, Tang S, El-Khechen D, Parker AS, Ross OA, Wszolek ZK. Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1. <span><span class="ref-journal">Mayo Clin Proc. </span>2015;<span class="ref-vol">90</span>:366–71.</span> [<a href="/pmc/articles/PMC4354704/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4354704</span></a>] [<a href="/pubmed/25659636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25659636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.tomlinson.2010.3530">Tomlinson SE, Tan SV, Kullmann DM, Griggs RC, Burke D, Hanna MG, Bostock H. Nerve excitability studies characterize Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1. <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>:3530–40.</span> [<a href="/pmc/articles/PMC2995887/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2995887</span></a>] [<a href="/pubmed/21106501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21106501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.trist_nclavijo.2016.1743">Trist&#x000e1;n-Clavijo E, Scholl FG, Macaya A, Iglesias G, Rojas AM, Lucas M, Castellano A, Martinez-Mir A. Dominant-negative mutation p.Arg324Thr in KCNA1 impairs Kv1.1 channel function in episodic ataxia. <span><span class="ref-journal">Mov Disord. </span>2016;<span class="ref-vol">31</span>:1743–8.</span> [<a href="/pubmed/27477325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27477325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.vance.1984.78s">Vance JM, Pericak-Vance MA, Payne CS, Coin JT, Olanow CW. Linkage and genetic analysis in adult onset periodic vestibulo-cerebellar ataxia: report of a new family. <span><span class="ref-journal">Am J Hum Genet. </span>1984;<span class="ref-vol">36</span>:78S.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.vandyke.1975.109">VanDyke DH, Griggs RC, Murphy MJ, Goldstein MN. Hereditary myokymia and periodic ataxia. <span><span class="ref-journal">J Neurol Sci. </span>1975;<span class="ref-vol">25</span>:109–18.</span> [<a href="/pubmed/1170284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1170284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.zerr.1998.2842">Zerr P, Adelman JP, Maylie J. Episodic ataxia mutations in Kv1.1 alter potassium channel function by dominant negative effects or haploinsufficiency. <span><span class="ref-journal">J Neurosci. </span>1998;<span class="ref-vol">18</span>:2842–8.</span> [<a href="/pmc/articles/PMC6792579/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6792579</span></a>] [<a href="/pubmed/9526001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9526001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ea1.REF.zuberi.1999.817">Zuberi SM, Eunson LH, Spauschus A, De Silva R, Tolmie J, Wood NW, McWilliam RC, Stephenson JP, Kullmann DM, Hanna MG. A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. <span><span class="ref-journal">Brain. </span>1999;<span class="ref-vol">122</span>:817–25.</span> [<a href="/pubmed/10355668" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10355668</span></a>]</div></li></ul></div></div><div id="ea1.Chapter_Notes"><h2 id="_ea1_Chapter_Notes_">Chapter Notes</h2><div id="ea1.Acknowledgments"><h3>Acknowledgments</h3><p>The financial support of Telethon (GGP11188), Ministero della Salute (GR-2009-1580433), and Fondazione Cassa di Risparmio di Perugia to MP is gratefully acknowledged. MGH is supported by an MRC Centre Grant (G0601943).</p></div><div id="ea1.Author_History"><h3>Author History</h3><p>Maria Cristina D'Adamo, PhD (2010-present)<br />Giuseppe Di Giovanni, PhD; Istituto Euro-Mediterraneo di Scienza e Tecnologia (2012-2015)<br />Michael G Hanna, BSc (Hons), MD, FRCP; UCL Institute of Neurology (2010-2015)<br />Sonia M Hasan, PhD (2018-present)<br />Mauro Pessia, PhD; Istituto Euro-Mediterraneo di Scienza e Tecnologia (2010-2015)</p></div><div id="ea1.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>1 November 2018 (aa) Revision: findings reported by <a class="bk_pop" href="#ea1.REF.rogers.2018.1748">Rogers et al [2018]</a>; Clinical Description</div></li><li class="half_rhythm"><div>31 May 2018 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 June 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 August 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 February 2010 (me) Review posted live</div></li><li class="half_rhythm"><div>21 April 2009 (mp) Initial submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK25442</span><span class="label">PMID: <a href="/pubmed/20301785" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301785</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/gale-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ea2/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK25442&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK25442/?report=reader">PubReader</a></li><li><a href="/books/NBK25442/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK25442" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK25442" style="display:none" title="Cite this Page"><div class="bk_tt">Hasan SM, D'Adamo MC. Episodic Ataxia Type 1. 2010 Feb 9 [Updated 2018 Nov 1]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK25442/pdf/Bookshelf_NBK25442.pdf">PDF version of this page</a> (595K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ea1.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ea1.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ea1.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ea1.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ea1.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ea1.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ea1.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ea1.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ea1.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ea1.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ea1.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3736[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KCNA1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK25442+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1950120" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1950120" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1950120" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1950120" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26347608" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New insights into the pathogenesis and therapeutics of episodic ataxia type 1.</a><span class="source">[Front Cell Neurosci. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New insights into the pathogenesis and therapeutics of episodic ataxia type 1.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">D'Adamo MC, Hasan S, Guglielmi L, Servettini I, Cenciarini M, Catacuzzeno L, Franciolini F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Front Cell Neurosci. 2015; 9:317. Epub 2015 Aug 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301512" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Weber F, Lehmann-Horn F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301674" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Episodic Ataxia Type 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Episodic Ataxia Type 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Spacey S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301785" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301785" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04170f75f66d18aa69855f">Episodic Ataxia Type 1 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Episodic Ataxia Type 1 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:12:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE896F1AE040D5C10000000004EF0236&amp;ncbi_session=CE896F1AE04170F1_1263SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK25442%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK25442&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK25442/&amp;ncbi_pagename=Episodic Ataxia Type 1 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE896F1AE04170F1_1263SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>